Jeffrey Bornstein

Company: Mediar Therapeutics

Job title: Chief Medical Officer

Seminars:

Panel Discussion: How Early Clinical Learnings Can Inform Smarter Preclinical Strategy for Antifibrotic Drug Development 10:00 am

As more antifibrotics enter early-phase clinical trials, translating bedside learnings back into the lab has never been more important. This panel gathers experts in early clinical development to examine how clinical signals, can be mined to refine target selection, guide biomarker validation, and improve preclinical model design. How Phase 2 outcomes including responder subtypes are…Read more

day: Conference Day Two

Using Biomarkers to Support a Precision Medicine Approach to Antifibrotic Drug Development 2:30 pm

Demonstrating target engagement early in your program Exploring the impact of engaging your target in downstream biomarkers Applying the observed effect of downstream biomarkers to select the patient population for late-stage clinical developmentRead more

day: Conference Day One